Show simple item record

AuthorChemaitelly, Hiam
AuthorYassine, Hadi M.
AuthorBenslimane, Fatiha M.
AuthorAl Khatib, Hebah A.
AuthorTang, Patrick
AuthorHasan, Mohammad R.
AuthorMalek, Joel A.
AuthorCoyle, Peter
AuthorAyoub, Houssein H.
AuthorAl Kanaani, Zaina
AuthorAl Kuwari, Einas
AuthorJeremijenko, Andrew
AuthorKaleeckal, Anvar Hassan
AuthorLatif, Ali Nizar
AuthorShaik, Riyazuddin Mohammad
AuthorAbdul Rahim, Hanan F.
AuthorNasrallah, Gheyath K.
AuthorAl Kuwari, Mohamed Ghaith
AuthorAl Romaihi, Hamad Eid
AuthorAl-Thani, Mohamed H.
AuthorAl Khal, Abdullatif
AuthorButt, Adeel A.
AuthorBertollini, Roberto
AuthorAbu-Raddad, Laith J.
Available date2021-10-20T07:59:40Z
Publication Date2021-09-01
Publication NameNature Medicine
Identifierhttp://dx.doi.org/10.1038/s41591-021-01446-y
CitationChemaitelly, H., Yassine, H.M., Benslimane, F.M. et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med 27, 1614–1621 (2021). https://doi.org/10.1038/s41591-021-01446-y
ISSN10788956
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85110038106&origin=inward
URIhttp://hdl.handle.net/10576/24582
AbstractThe SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with ‘wild-type’ variants in a randomized clinical trial. Here, we assess the real-world effectiveness of this vaccine against SARS-CoV-2 variants of concern, specifically B.1.1.7 (Alpha) and B.1.351 (Beta), in Qatar, a population that comprises mainly working-age adults, using a matched test-negative, case-control study design. We show that vaccine effectiveness was negligible for 2 weeks after the first dose, but increased rapidly in the third and fourth weeks immediately before administration of a second dose. Effectiveness against B.1.1.7 infection was 88.1% (95% confidence interval (CI): 83.7–91.5%) ≥14 days after the first dose but before the second dose, and was 100% (95% CI: 91.8–100.0%) ≥14 days after the second dose. Analogous effectiveness against B.1.351 infection was 61.3% after the first dose (95% CI: 56.5–65.5%) and 96.4% after the second dose (95% CI: 91.9–98.7%). Effectiveness against any severe, critical or fatal COVID-19 disease due to any SARS-CoV-2 infection (predominantly B.1.1.7 and B.1.351) was 81.6% (95% CI: 71.0–88.8%) and 95.7% (95% CI: 73.4–99.9%) after the first and second dose, respectively. The mRNA-1273 vaccine is highly effective against B.1.1.7 and B.1.351 infections, whether symptomatic or asymptomatic, and against any COVID-19 hospitalization and death, even after a single dose.
Languageen
SubjectEpidemiology
RNA vaccines
Viral infection
TitlemRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
TypeArticle
Pagination1614-1621
Issue Number9
Volume Number27
ESSN1546-170X
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record